RNA interference therapy

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Japan & United States:  −        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated…

Read More »